Theme 13 Clinical management and support.

Gespeichert in:
Bibliographische Detailangaben
Titel: Theme 13 Clinical management and support.
Autoren: Crook, Ashley, Hogden, Anne, Mumford, Virginia, Blair, Ian P., Williams, Kelly L., Rowe, Dominic B., Fell, Rosie, moura Campos, Cecilia Helena, Cruz, Fabiana Theodoro, Leico Oda, Adriana, O'Brien, Mary R., Oliver, David, Aoun, Samar, Mc Dermott, Christopher J., Kirton, Jennifer, Pearson, Emma, Lucia, Diana, McCombe, Pamela A., Henderson, Robert D., Steyn, Frederik J.
Quelle: Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration; 2019 Supplement, Vol. 20, p327-347, 21p
Schlagwörter: SOCIAL surveys, CAREER development
Abstract: 2017; The 28th International Symposium on ALS/MND. 32 Costello J. (2012) Preserving legacy: A guide to Message Banking a patient's voice. A phase 1 study to evaluate bioequivalence between BHV-0223 40 mg zydis sublingual formulation and riluzole 50mg oral tablet in healthy volunteers. A phase 1 study to evaluate bioequivalence between BHV-0223 40 mg zydis sublingual formulation and riluzole 50mg oral tablet in healthy volunteers. https://www.biohavenpharma.com/sites/default/files/documents/bvh-0223-bioequivalence-aanem-2018.pdf. [Extracted from the article]
Copyright of Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Datenbank: Complementary Index
Beschreibung
Abstract:2017; The 28th International Symposium on ALS/MND. 32 Costello J. (2012) Preserving legacy: A guide to Message Banking a patient's voice. A phase 1 study to evaluate bioequivalence between BHV-0223 40 mg zydis sublingual formulation and riluzole 50mg oral tablet in healthy volunteers. A phase 1 study to evaluate bioequivalence between BHV-0223 40 mg zydis sublingual formulation and riluzole 50mg oral tablet in healthy volunteers. https://www.biohavenpharma.com/sites/default/files/documents/bvh-0223-bioequivalence-aanem-2018.pdf. [Extracted from the article]
ISSN:21678421
DOI:10.1080/21678421.2019.1647002